-+ 0.00%
-+ 0.00%
-+ 0.00%
12 Health Care Stocks Moving In Tuesday's After-Market Session
Share
Listen to the news

Gainers

  • Quince Therapeutics (NASDAQ:QNCX) shares increased by 35.0% to $0.22 during Tuesday's after-market session. The company's market cap stands at $4.8 million.
  • Decoy Therapeutics (NASDAQ:DCOY) stock rose 25.64% to $7.3. The company's market cap stands at $3.1 million.
  • Iridex (NASDAQ:IRIX) shares increased by 22.33% to $1.26. The market value of their outstanding shares is at $17.1 million.
  • NewcelX (NASDAQ:NCEL) shares rose 13.94% to $2.37. The company's market cap stands at $9.7 million.
  • Galectin Therapeutics (NASDAQ:GALT) stock rose 9.36% to $2.4. The company's market cap stands at $168.5 million.
  • Alvotech (NASDAQ:ALVO) shares increased by 7.96% to $3.66. The company's market cap stands at $1.1 billion.

Losers

  • Cuprina Holdings (Cayman) (NASDAQ:CUPR) shares declined by 17.2% to $0.5 during Tuesday's after-market session. The company's market cap stands at $2.9 million.
  • Processa Pharma (NASDAQ:PCSA) shares fell 7.15% to $2.67. The company's market cap stands at $7.4 million.
  • Impact BioMedical (AMEX:IBO) shares fell 6.58% to $0.63. The market value of their outstanding shares is at $69.0 million.
  • Cyclerion Therapeutics (NASDAQ:CYCN) shares decreased by 6.33% to $3.26. The company's market cap stands at $15.7 million.
  • Capricor Therapeutics (NASDAQ:CAPR) shares fell 6.07% to $30.03. The market value of their outstanding shares is at $1.8 billion.
  • Artelo Biosciences (NASDAQ:ARTL) stock fell 6.04% to $6.85. The market value of their outstanding shares is at $4.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending